Patient characteristics
Characteristics . | . |
|---|---|
| General | |
| No. patients | 21 |
| Male/female ratio | 15:6 |
| Median age, y (range) | 66 (50-83) |
| Evaluable for toxicity | 21 |
| Evaluable for response | 20 |
| Median disease duration, mo (range) | 10 (2-25) |
| Diagnosis* | |
| RA | 2 |
| RAEB | 7 |
| RAEB-T | 2 |
| CMMoL | 10 |
| IPSS score† | |
| Low | 2 |
| Intermediate-1 | 8 |
| Intermediate-2 | 5 |
| High | 6 |
| ras Mutations | |
| n-ras | 3 |
| k-ras | 1 |
| Cytogenetics | |
| Diploid | 10 |
| Monosomy 7 | 4 |
| −5/5q- | 3 |
| 13q- | 1 |
| Trisomy 8 | 1 |
| Other | 5 |
| Prior therapy | |
| Topotecan | 5 |
| Ara-C | 5 |
| Cytoxan | 2 |
| Thalidomide | 3 |
| EPO | 4 |
| IL-11 | 4 |
| Fludarabine | 2 |
| ATG/CSA | 1 |
| SCF | 1 |
| None | 6 |
Characteristics . | . |
|---|---|
| General | |
| No. patients | 21 |
| Male/female ratio | 15:6 |
| Median age, y (range) | 66 (50-83) |
| Evaluable for toxicity | 21 |
| Evaluable for response | 20 |
| Median disease duration, mo (range) | 10 (2-25) |
| Diagnosis* | |
| RA | 2 |
| RAEB | 7 |
| RAEB-T | 2 |
| CMMoL | 10 |
| IPSS score† | |
| Low | 2 |
| Intermediate-1 | 8 |
| Intermediate-2 | 5 |
| High | 6 |
| ras Mutations | |
| n-ras | 3 |
| k-ras | 1 |
| Cytogenetics | |
| Diploid | 10 |
| Monosomy 7 | 4 |
| −5/5q- | 3 |
| 13q- | 1 |
| Trisomy 8 | 1 |
| Other | 5 |
| Prior therapy | |
| Topotecan | 5 |
| Ara-C | 5 |
| Cytoxan | 2 |
| Thalidomide | 3 |
| EPO | 4 |
| IL-11 | 4 |
| Fludarabine | 2 |
| ATG/CSA | 1 |
| SCF | 1 |
| None | 6 |
Ara-C indicates cytosine arabinoside; ATG/CSA, antithymocyte globulin/cyclosporine; EPO, erythropoietin; IPSS, International Prognosis Scoring System; and SCF, stem cell factor.
Study initiation predated the new World Health Organization (WHO) criteria for MDS classification.31 French-American-British (FAB) criteria were used.32
IPSS was used.33